（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：爱尔眼科股价一直在不断的下跌，是不是预示着2025 年的年报将大幅下降？ 爱尔眼科（300015.SZ）2月3日在投资者互动平台表示，公司经营正常，2025年度报告将于2026年4月24 日披露，敬请关注。 ...

Core Insights - The 2025 Hurun China Brand List was released, marking the 20th edition of the list, which now includes non-Chinese brands that serve Chinese consumers for the first time [1][6] - Apple tops the list with a brand value of 1.11 trillion RMB, followed by Kweichow Moutai at 795 billion RMB, and WeChat at 325 billion RMB, which saw the highest growth among Chinese brands [4][5] Brand Rankings - The top five brands are: 1. Apple - 1,110 billion RMB (USA, Consumer Electronics) [4] 2. Kweichow Moutai - 795 billion RMB (China) [4] 3. WeChat - 325 billion RMB (China, +38%) [4] 4. Douyin - 280 billion RMB (China, +14%) [4] 5. Tesla - 270 billion RMB (USA, New Entry) [4] Industry Insights - The consumer electronics sector has surpassed the liquor industry to become the highest-valued industry on the list, while liquor remains the highest-valued industry for domestic brands [5] - A total of 386 brands from China made the list, leading the rankings, followed by 46 from the USA and 19 from France [5] Regional Highlights - Hunan province has six brands on the list, including Furong Wang at 18th, Aier Eye Hospital at 131st, and Mango TV at 214th [5] - Shanghai is the city with the most brands on the list, contributing 136 brands, followed by Beijing with 104 [5] New Entries - 212 new brands were added to the list, primarily from the food and beverage and daily chemical industries, with notable entries like Red Bull and Coca-Cola [5][6] - The automotive sector also saw significant new entries, including Tesla and Toyota [5] Brand Value Growth - The total brand value of the listed brands reached nearly 8.8 trillion RMB, an increase of 47% from the previous year [6] - The thresholds for the top 300, 200, and 100 brands have increased, indicating a rise in brand value requirements [6]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

Core Viewpoint - The successful implantation of the "EVO+ICL(V5)" artificial lens at the Eye Hospital in Yongzhou marks a significant advancement in vision correction technology, particularly benefiting athletes like Gao Xiang who face challenges due to high myopia [1][9]. Group 1: Patient Experience and Needs - Gao Xiang, a key player in the Xiangchao championship team, struggled with severe myopia of approximately 800 degrees, which affected his performance on the field [3]. - The decision to undergo surgery was driven by the need for clear vision during training and competitions, as wearing contact lenses caused discomfort and impacted his performance [3][5]. Group 2: Technological Advancements - The "EVO+ICL(V5)" lens is recognized for its advantages such as non-invasive corneal procedures, strong reversibility, and a wide range of correction, making it a preferred choice for athletes [4]. - The V5 lens features an expanded optical zone of 6.1mm, enhancing night vision and reducing visual disturbances like glare and halos, which is crucial for athletes [4]. Group 3: Surgical Process and Expertise - Prior to the surgery, over 20 detailed eye examinations were conducted to assess Gao Xiang's eye condition, ensuring a personalized surgical plan was developed [5][7]. - Dr. Huang Haitao, with over 30 years of experience and nearly 20,000 surgeries performed, led the operation, emphasizing the importance of safety and tailored solutions for athletes [7]. Group 4: Post-Surgery Outcomes - Post-operative assessments showed Gao Xiang achieving a vision of 1.2 in the right eye and 1.0+ in the left eye, leading to a significant improvement in his visual clarity and overall training focus [7]. - Gao Xiang expressed high satisfaction with the surgery and the professional service provided by the Eye Hospital, highlighting the positive impact on his athletic performance [7]. Group 5: Industry Recognition - During the 14th "Caring for Myopia・Smile Forum," Aier Eye Hospital received dual recognition, with six hospitals becoming part of the "EVO+ ICL(V5) Clinical Research Alliance" and 14 experts recognized as initial clinical application specialists [9]. - The successful surgery of Gao Xiang not only showcases the technology's benefits for athletes but also reinforces Aier Eye Hospital's strength in the field of refractive surgery [9].

Core Insights - The medical services sector experienced a rise of 1.61% on January 29, with Tongce Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Services Sector Performance - Tongce Medical (600763) closed at 47.49, with a gain of 5.14%, and a trading volume of 206,500 shares, amounting to a transaction value of 9.65 billion [1] - Other notable performers included: - Digital Human (920670) at 20.26, up 3.90%, with a transaction value of 2.08 billion [1] - Meinian Health (002044) at 7.28, up 3.70%, with a transaction value of 24.68 billion [1] - Tiger Medical (300347) at 58.91, up 3.51%, with a transaction value of 7.82 billion [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.146 billion from institutional investors, while retail investors experienced a net outflow of 1.043 billion [2][3] - Key stocks with significant capital flow included: - WuXi AppTec (603259) with a net inflow of 306 million, representing 5.87% of total capital [3] - Aier Eye Hospital (300015) with a net inflow of 228 million, representing 15.83% of total capital [3] - Meinian Health (002044) with a net inflow of 163 million, representing 6.60% of total capital [3]

据中国经济网记者不完全统计，过去一年时间里，爱尔眼科及其下属医院2度被相关监管部门通报，4度 被处罚。 广西壮族自治区市场监督管理局公众号2025年1月14日公布了2024年度民生领域虚假违法广告典型案 例。其中案例3为贵港爱尔眼科医院有限公司广告违法案件。经查，贵港爱尔眼科医院有限公司利用网 络媒介发布广告，该医疗广告内容与《医疗广告审查证明》核准的广告成品样件内容不一致。2024年3 月，贵港市港北区市场监管局对当事人作出行政处罚。 中国经济网北京1月29日讯信用中国网站显示，横州爱尔眼科（300015）医院有限公司近期新增行政处 罚决定书(横卫医罚﹝2026﹞1号)。 横州爱尔眼科医院有限公司未经备案开展义诊活动，该行为违反了《医疗机构管理条例》第二十三条的 规定，依据《医疗机构管理条例》第四十三条第二款的规定，横州市卫生健康局给予罚款人民币捌仟元 整(8000.00)的行政处罚。 信网23日报道《丽水爱尔眼科重复收费造成医疗保障基金损失被罚7.7万余元》显示，近日，丽水爱尔 眼科医院有限公司因分解收费、重复收费等造成医疗保障基金损失，被罚77543.75元，并退回违规行为 造成的基金损失48346.7 ...

中国"1+8+N"战略推进以及海外业务持续双位数增长，共同驱动公司整体收入持续提升。国内业务方 面，公司于2022 年提出新十年"1+8+N"战略，即着力打造1 家世界级眼科医学中心（长沙爱尔）、8 家 国家及区域眼科医学中心（北京、上海、广州、深圳、成都、重庆、武汉、沈阳）、N 家省域一流和地 区领先的眼科医院。截至1H25末，公司境内医院355 家，门诊部240 家。展望未来，随着"1+8+N"战略 的推进和落地，我们相信重点医院辐射作用有望持续加强，门店布局有望完善丰富，带动集团中国收入 持续增长。海外业务方面，公司海外收入于2020-2024 年间实现17.6% CAGR，1H25 实现16.5%YoY 增 速，主要受欧洲子公司Clínica Baviera 和东南亚子公司ISEC 收入增长驱动。展望未来，国际市场空间潜 力巨大，随着公司现有海外业务收入的进一步提升以及未来潜在的海外并购落地，我们认为国际化收入 可在中长期助推公司收入增长。 首次覆盖给予"买入"评级及医疗服务行业首选推荐，目标价人民币14.0 元。我们预计公司于 2025E/2026E/2027E 实现228/250/273亿元收入， ...

Group 1 - The core viewpoint of the report is that Aier Eye Hospital (300015.SZ) is rated as "Buy" with a target price of 14.0 yuan [1] - The private ophthalmology medical service market in China has grown to nearly 100 billion yuan, accounting for approximately 40% of the overall ophthalmology medical service market [1] - Aier Eye Hospital is a global leader in ophthalmology medical services, with operations covering multiple markets including China, Europe, and Southeast Asia [1] - The implementation of China's "1+8+N" strategy and the continuous double-digit growth of overseas business are driving the overall revenue increase of the company [1]

Market Overview - The medical services sector experienced a decline of 1.64% on January 28, with Guangzheng Eye Care leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Individual Stock Performance - Guangzheng Eye Care (002524) saw a significant drop of 8.63%, closing at 5.08, with a trading volume of 1.41 million shares and a transaction value of 721 million [2] - Other notable declines included Yinuosi (688710) down 7.45% and Haoyuan Pharmaceutical (688131) down 6.49% [2] - In contrast, ST Zhongzhu (600568) increased by 1.43%, closing at 2.83, with a trading volume of 338,300 shares [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 1.697 billion in institutional funds, while retail investors saw a net inflow of 1.544 billion [2] - Notable stocks with significant capital inflow included Sunshine Nuohe (688621) with a net inflow of 27.668 million from institutional investors [3] - Conversely, stocks like ST Zhongzhu (600568) and Wanbang Medical (301520) faced net outflows from institutional investors [3]

证券代码：300015 股票简称：爱尔眼科 公告编号：2026-005 爱尔眼科医院集团股份有限公司 关于使用部分闲置自有资金进行现金管理的实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日召开第六届董事会第三十二次会议，审议通过了《关于使用部分闲置自有资金 进行现金管理的议案》，同意公司在保证日常经营资金需求和资金安全的前提下， 使用不超过人民币 15 亿元的闲置自有资金购买安全性高、流动性好、风险性低 的理财产品，期限为自公司第六届董事会第三十二次会议决议之日起 12 个月。 在上述额度及期限内，资金可循环滚动使用，由公司财务中心负责具体购买事宜。 上述内容详见公司 2025 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露 的相关公告。 根据上述决议，公司全资子公司爱尔眼科国际（香港）有限公司于近期办理 了投资理财业务。现就具体事项公告如下： 一、本次使用部分暂时闲置自有资金进行现金管理的实施情况 产品名称：花旗银行双货币可转换存款 理财币 ...